CLDN18.2 Target Drug Development Accelerates 2024 Brings New Opportunities for Adenocarcinoma Treatment

The development of drugs targeting Claudin 18.2 (CLDN18.2) has gained momentum, heralding new hope in gastric cancer treatment. On December 31, 2024, the targeted drug Zolbetuximab from Astellas received approval in China, marking it as the world's first and only approved CLDN18.2-targeted therapy. Following this, on January 16, 2024, Innovent Biologics announced that its CLDN18.2 drug — IBI343, an antibody-drug conjugate (ADC), was included in the Breakthrough Therapy Designation (BTD) list, showcasing the rapid rise of domestic pharmaceutical companies in this field.

According to Frost & Sullivan, the global gastric cancer drug market is expected to grow from $22.1 billion in 2024 to $36.4 billion by 2030, with a CAGR of 8.7%. In the CLDN18.2 antibody market, it is projected that from 2025 to 2035, the markets in the U.S. and China will increase from $252 million and $200 million to $4.036 billion and $3.744 billion, respectively, with CAGRs of 32.0% and 33.5%. This market potential provides extensive opportunities for Chinese pharmaceutical enterprises.

As a country with a high incidence of gastrointestinal cancers, China ranks high in both gastric cancer incidence and mortality rates. According to the WHO data from 2020, there were approximately 478,000 new gastric cancer cases and 373,000 deaths in China. Despite the continuous improvement in treatment methods, the prognosis for late-stage gastric cancer patients remains unsatisfactory, creating a pressing demand for new targeted therapies.

CLDN18.2 shows high expression in both gastric and pancreatic cancers, making it a promising target for anti-tumor therapies. Currently, over 70 drugs targeting CLDN18.2 are in active development globally, including monoclonal antibodies, bispecific antibodies, ADCs, and CAR-T therapies. Notably, seven domestically developed drugs have progressed to Phase III clinical trials, demonstrating strong R&D potential.

IBI343 from Innovent Biologics has made significant progress in its Phase III trials in Japan, likely becoming the first CLDN18.2 ADC approved globally. Furthermore, the LM302 from Lianxin Pharma is also advancing, having established a collaboration with Turning Point for exclusive overseas licensing. Heng Rui Pharma and other companies are exploring the applications of CLDN18.2, striving for optimal efficacy across various treatment strategies.

As research into the CLDN18.2 target deepens and drug development accelerates, this not only provides new treatment options for gastric cancer patients but also holds promise for broad clinical applications in other solid tumors. With Astellas’ Zolbetuximab successfully hitting the market, more innovative targeted therapies are expected to emerge, offering new hope for patients.